Drug Names
EMA's CHMP Recommends BMS's Opdivo, Chemo for Neoadjuvant PD-L1-Positive NSCLC
If approved, the drug combination will be the first immunotherapy-based treatment available in the neoadjuvant setting for NSCLC patients in Europe.
Panbela Therapeutics, Moffitt Cancer Center Testing Immunotherapy Enhancer in STK11-Mutant NSCLC
The partners will evaluate Panbela's eflornithine with Merck's Keytruda in a Phase I/II trial as proof of concept for modulating the immune system using polyamines and standard therapies.
Tibsovo added to a standard two-drug treatment regimen extended event-free survival and reduced treatment failure in patients with IDH1-mutant acute myeloid leukemia.
AstraZeneca Sees New Lung Cancer Indication for Tagrisso, Chemo in FLAURA2 Data
Based on high-level results from the trial, the firm believes the combination could be a new first-line option for patients with advanced EGFR-mutated NSCLC.
Personalis, Ono Pharmaceutical, Japan National Cancer Center Partner on Opdivo Rectal Cancer Trial
In the multicenter VOLTAGE-2 trial, investigators will compare results of the company's tests with standard-of-care measures of drug response.